Patents by Inventor Thomas Shenk

Thomas Shenk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11008551
    Abstract: A method for enhancing infectivity of HCMV virus particles is provided.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: May 18, 2021
    Assignee: THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventors: Thomas Shenk, Nicole Gudleski O'Regan, Todd M. Greco, Ileana M. Cristea
  • Patent number: 10813934
    Abstract: Agents and methods of inhibiting or improving the growth of viruses are provided.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: October 27, 2020
    Assignee: THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventors: Thomas Shenk, Emre Koyuncu, Ileana M. Cristea
  • Patent number: 10788492
    Abstract: The present application demonstrates that sirtuin 4 (SIRT4) acts as a cellular lipoamidase that negatively regulates pyruvate dehydrogenase complex (PDHC) activity through hydrolysis of its lipoamide cofactors.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: September 29, 2020
    Assignee: THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventors: Thomas Shenk, Todd M. Greco, Ileana M. Cristea, Rommel A. Mathias, Adam Oberstein
  • Publication number: 20190358317
    Abstract: Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.
    Type: Application
    Filed: April 11, 2019
    Publication date: November 28, 2019
    Inventors: Thomas Shenk, Dai Wang
  • Publication number: 20190218524
    Abstract: A method is provided to improve virus production is an infected host cell by culturing the infected cell in an effective amount of alpha-ketoglutarate.
    Type: Application
    Filed: March 27, 2019
    Publication date: July 18, 2019
    Inventors: Emre Koyuncu, Ileana M. Cristea, Thomas Shenk
  • Patent number: 10300130
    Abstract: Methods of increasing diversity in cytomegalovirus vaccines through the selection of cell type in which the virus is propagated, and the use of cytomegalovirus produced by those methods in the development of vaccine compositions, are disclosed. Vaccine compositions comprising CMV isolated from epithelial cells are also disclosed.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: May 28, 2019
    Assignee: The Trustees of Princeton University
    Inventors: Thomas Shenk, Dai Wang
  • Publication number: 20190094225
    Abstract: The present application demonstrates that sirtuin 4 (SIRT4) acts as a cellular lipoamidase that negatively regulates pyruvate dehydrogenase complex (PDHC) activity through hydrolysis of its lipoamide cofactors.
    Type: Application
    Filed: January 15, 2015
    Publication date: March 28, 2019
    Inventors: Thomas Shenk, Todd M. Greco, IIeana M. Cristea, Rommel A. Mathias, Adam Oberstein
  • Patent number: 10174290
    Abstract: A method for enhancing infectivity of HCMV virus particles is provided.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: January 8, 2019
    Assignee: THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventors: Thomas Shenk, Nicole Gudleski O'Regan, Todd M. Greco, Ileana M. Cristea
  • Publication number: 20180346885
    Abstract: A method for enhancing infectivity of HCMV virus particles is provided.
    Type: Application
    Filed: August 3, 2018
    Publication date: December 6, 2018
    Inventors: Thomas Shenk, Nicole Gudleski O'Regan, Todd M. Greco, Ileana M. Cristea
  • Publication number: 20180298348
    Abstract: The present disclosure provides a method to enhance the production of virus in cultured fibroblasts by supplementing the cells with a TCA cycle intermediate, aketoglutarate, or a derivative thereof, wherein virus production is enhanced compared to the same method canied out in the absence of a-ketoglutarate or the derivative thereof. In view of the art, the method provides an unexpected improvement on methods routinely practiced.
    Type: Application
    Filed: June 20, 2018
    Publication date: October 18, 2018
    Inventors: Emre Koyuncu, Ileana M. Cristea, Thomas Shenk
  • Patent number: 9757407
    Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: September 12, 2017
    Assignee: The Trustees of Princeton University
    Inventors: Josh Munger, Bryson Bennett, Thomas Shenk, Joshua Rabinowitz
  • Publication number: 20170014504
    Abstract: Methods of increasing diversity in cytomegalovirus vaccines through the selection of cell type in which the virus is propagated, and the use of cytomegalovirus produced by those methods in the development of vaccine compositions, are disclosed. Vaccine compositions comprising CMV isolated from epithelial cells are also disclosed.
    Type: Application
    Filed: July 29, 2016
    Publication date: January 19, 2017
    Inventors: Thomas Shenk, Dai Wang
  • Publication number: 20160346309
    Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.
    Type: Application
    Filed: December 21, 2015
    Publication date: December 1, 2016
    Inventors: Josh Munger, Bryson Bennett, Thomas Shenk, Joshua Rabinowitz
  • Publication number: 20160296523
    Abstract: Agents and methods of inhibiting or improving the growth of viruses are provided.
    Type: Application
    Filed: June 20, 2016
    Publication date: October 13, 2016
    Inventors: Thomas Shenk, Emre Koyuncu, Ileana M. Cristea
  • Patent number: 9439960
    Abstract: Methods of increasing diversity in cytomegalovirus vaccines through the selection of cell type in which the virus is propagated, and the use of cytomegalovirus produced by those methods in the development of vaccine compositions, are disclosed. Vaccine compositions comprising CMV isolated from epithelial cells are also disclosed.
    Type: Grant
    Filed: October 1, 2008
    Date of Patent: September 13, 2016
    Assignee: The Trustees of Princeton University
    Inventors: Thomas Shenk, Dai Wang
  • Publication number: 20160130565
    Abstract: A method for improving virus production in a host cell infected with the virus is provided.
    Type: Application
    Filed: November 6, 2015
    Publication date: May 12, 2016
    Inventors: Thomas Shenk, Emre Koyuncu, Joshua D. Rabinowitz
  • Patent number: 9212349
    Abstract: A method for improving virus production in a host cell infected with the virus is provided.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: December 15, 2015
    Assignee: THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventors: Thomas Shenk, Emre Koyuncu, Joshua D. Rabinowitz
  • Publication number: 20150335657
    Abstract: This document relates to compounds useful for modulating sirtuin enzymes. For example, the compounds provided herein are useful as broad spectrum antiviral agents. In addition, the compounds provided herein may be used in the treatment of other disorders associated with sirtuin enzymes, such as diseases related to aging and stress, blood clotting disorders, cancer, cardiovascular diseases, diabetes, inflammation, neurodegenerative diseases, and obesity.
    Type: Application
    Filed: May 4, 2015
    Publication date: November 26, 2015
    Inventors: Thomas Shenk, Emre Koyuncu, Hahn Kim, Ileana Cristea, David MacMillan
  • Patent number: 9168269
    Abstract: The present invention provides methods and compounds for treating viral infections using modulators of host cell enzymes relating to long chain fatty acid and lipid droplet metabolism. It includes a method of treating viral infections using triacsin C and its relatives, analogs and derivatives as well as other inhibitors of long chain fatty acid metabolism and lipid droplet metabolism.
    Type: Grant
    Filed: February 18, 2011
    Date of Patent: October 27, 2015
    Assignee: THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventors: Emre Koyuncu, Joshua D. Rabinowitz, Thomas Shenk
  • Patent number: 9149445
    Abstract: A method of treating or preventing a viral infection in a mammal by administering a compound or pharmaceutically acceptable derivative thereof that inhibits a phosphatidic acid synthesis enzyme.
    Type: Grant
    Filed: July 27, 2010
    Date of Patent: October 6, 2015
    Assignee: THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventors: Sean Liu, Joshua D. Rabinowitz, Thomas Shenk